© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 2 Would you prefer to know if your chemotherapy is working or not NOW Would you like to endure 26 weeks of chemotherapy side effects? OR

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 3 Problem: Adverse Side Effects  50% of breast cancer patients receive chemotherapy  75% of chemo patients derive no long term benefit  All patients suffer adverse side effects

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 4 Solution: RDA™ improved chemotherapy management  First “Real Time” chemotherapy guidance tool  Only prognostic test to measure response to chemotherapy early in treatment  Discovered in clinical trial (NCIC MA.22)  Protected by broad patents

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 5 Benefits for Patients, Physicians and Payers  For non responding patients, treatment can be altered quickly  Significant reduction in adverse effects  Switch to alternate treatment improves survival benefit  Objective & useful tool for physicians  Cost savings for healthcare payers ($20k - $60K / patient) Maureen E. Trudeau MD, FRCPC Head, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Head, Systemic Therapy Program, Odette Cancer Centre, Toronto, Canada “ RDA holds the prospect of providing oncologists with an extremely valuable method for managing the chemotherapy of their breast cancer patients ”

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 6 Technology : RNA Disruption Assay (RDA™)  National Cancer Institute of Canada breast cancer trial (MA.22)  Clear discrimination between responders and non- responders  RDA strongly correlates with pathological complete response (pCR) at end of therapy  Negative Predictive Value = 0.99  False Negative 1% RDA™ Performance Characteristics

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 7 RDA ™ Clinical Scoring RDA ScoreClinical Guidance 1 Patient is a non-responder, chemotherapy is not working. Consider alternate approach NPV 0.99 False Negative Rate of Patient is a partial responder – chemotherapy should be continued 3 High level of RNA structural dysfunction – chemotherapy is working. Patient 3x more likely to achieve pCR than untested cohort PPV 0.17

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 8 RDA: Clinical System Chemotherapy selectedChemotherapy infusion Breast tumour biopsy Fine Needle Aspirate, 2 samples Tumour RNA FixativeRNA Disruption analysed at Rna DIAGNOSTICS central lab Raw data analysed by Rna DIAGNOSTICS using proprietary algorithms. Results transmitted to clinician

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 9 Management Team Management  CEO: Dr. Ken Pritzker, MD, FRCPC  Former Chief Pathology & Lab Medicine, Mount Sinai Hospital, Toronto, Cancer diagnostics expert  CSO: Dr. Amadeo Parissenti, PhD  Cancer Research Scientist, Laurentian University  VP Corporate Development: John Connolly, MBA  Former partner at MDS Capital Corp. – 15 year Medtech entrepreneur  CFO: John Jordan, MBA, CMA, CPA, ABV  Financial executive, experienced working with high growth technology companies Clinical Advisory Board  Maureen Trudeau, MA, MD, FRCPC - Head, Medical Oncology, Sunnybrook Health Sciences, Toronto, Canada  Michael Untch, MD, PhD– Head, German Breast Group, Berlin, Germany  Gunter von Minckwitz, MD, PhD – Chairman, German Breast Group, Frankfurt, Germany  Harry Bear, MD, PhD – Principal Investigator, NSABP, Virginia Commonwealth University, USA

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 10 Market Opportunity in Breast Cancer Size of Breast Cancer Market $525M # of Patients per year in the developed world 350,000 Sales Forecast by 2018 $100 M Total Addressable Market

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 11 Competition :Oncologists need better tools Physical Exam  Physical Exams do not predict efficacy  Imaging Over estimates efficacy  Too late to impact clinical decision making  Gene panels predict probability of 10 year recurrence  Don’t predict efficacy

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 12 Sales Forecast

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 13 Rna Diagnostics Inc.  Unique solution for serious cancer problem  Large market - $500M in Breast Cancer  Strong IP and clinical data  Clinical trials underway  Rapid route to market

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 14 “RDA: better chemotherapy management” Investor Presentation April 2013